AMYLYX PHARMACEUTICALS INC (AMLX) Stock Price, Quote, News and Overview
NASDAQ:AMLX - Nasdaq - US03237H1014 - Common Stock - Currency: USD
AMLX Quote, Performance and Key Statistics
3.3
-0.22 (-6.25%)
The current stock price of AMLX is 3.3 USD. In the past month the price decreased by -7.3%. In the past year, price decreased by -81.3%.
AMLX Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 67.21 | 829.40B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 27.44 | 390.99B | ||
| JNJ | JOHNSON & JOHNSON | 16.25 | 390.76B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 20.56 | 230.17B | ||
| MRK | MERCK & CO. INC. | 11.71 | 226.40B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 13.77 | 215.98B | ||
| PFE | PFIZER INC | 8.46 | 149.04B | ||
| SNY | SANOFI-ADR | 13.58 | 136.54B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 48.97 | 113.23B | ||
| GSK | GSK PLC-SPON ADR | 7.78 | 74.77B | ||
| ZTS | ZOETIS INC | 27.1 | 72.39B | ||
| TAK | TAKEDA PHARMACEUTIC-SP ADR | 31.95 | 44.58B |
Related stock screener links
About AMLX
Company Profile
Amylyx Pharmaceuticals, Inc. is a commercial-stage biotechnology company, which engages in the provision of therapies for neurodegenerative diseases and amyotrophic lateral sclerosis (ALS). The company is headquartered in Cambridge, Massachusetts and currently employs 384 full-time employees. The company went IPO on 2022-01-07. The firm is engaged in the discovery and development of treatments for neurodegenerative diseases. The firm is focused on the development and commercialization of its product candidate: AMX0035 for the treatment of Wolfram syndrome and for the treatment of progressive supranuclear palsy, and AMX0114, the Company’s antisense oligonucleotide targeting calpain-2 for the treatment of amyotrophic lateral sclerosis (ALS). AMX0035 is a dual-unfolded protein response (UPR)-Bax apoptosis inhibitor composed of PB and TURSO (also known as TUDCA). The Company’s Avexitide is an investigational, first-in-class glucagon-like peptide-1 (GLP-1) receptor antagonist that has been evaluated in five clinical trials for post-bariatric hypoglycemia (PBH) and has also been studied in congenital hyperinsulinism (HI), two indications characterized by hyperinsulinemic hypoglycemia.
Company Info
AMYLYX PHARMACEUTICALS INC
43 Thorndike Street
Cambridge MASSACHUSETTS US
Employees: 384
Company Website: https://www.amylyx.com/
Investor Relations: https://investors.amylyx.com/
Phone: 16176820917
AMYLYX PHARMACEUTICALS INC / AMLX FAQ
What is the stock price of AMYLYX PHARMACEUTICALS INC today?
The current stock price of AMLX is 3.3 USD. The price decreased by -6.25% in the last trading session.
What is the ticker symbol for AMYLYX PHARMACEUTICALS INC stock?
The exchange symbol of AMYLYX PHARMACEUTICALS INC is AMLX and it is listed on the Nasdaq exchange.
On which exchange is AMLX stock listed?
AMLX stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for AMYLYX PHARMACEUTICALS INC stock?
12 analysts have analysed AMLX and the average price target is 8.16 USD. This implies a price increase of 147.27% is expected in the next year compared to the current price of 3.3. Check the AMYLYX PHARMACEUTICALS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is AMYLYX PHARMACEUTICALS INC worth?
AMYLYX PHARMACEUTICALS INC (AMLX) has a market capitalization of 282.78M USD. This makes AMLX a Micro Cap stock.
How many employees does AMYLYX PHARMACEUTICALS INC have?
AMYLYX PHARMACEUTICALS INC (AMLX) currently has 384 employees.
What are the support and resistance levels for AMYLYX PHARMACEUTICALS INC (AMLX) stock?
AMYLYX PHARMACEUTICALS INC (AMLX) has a support level at 3.2 and a resistance level at 3.66. Check the full technical report for a detailed analysis of AMLX support and resistance levels.
Is AMYLYX PHARMACEUTICALS INC (AMLX) expected to grow?
The Revenue of AMYLYX PHARMACEUTICALS INC (AMLX) is expected to decline by -76.87% in the next year. Check the estimates tab for more information on the AMLX EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy AMYLYX PHARMACEUTICALS INC (AMLX) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of AMLX, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of AMLX, evaluating the profitability, health, valuation and growth aspects
- AMYLYX PHARMACEUTICALS INC (AMLX) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- AMYLYX PHARMACEUTICALS INC (AMLX) Sales and EPS estimates to see what analysts future expectations are.
- AMYLYX PHARMACEUTICALS INC (AMLX) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- AMYLYX PHARMACEUTICALS INC (AMLX) Insider and Institutional Ownership to learn about the owners and their transactions.
- AMYLYX PHARMACEUTICALS INC (AMLX) Stock Chart to make your own analysis
- AMYLYX PHARMACEUTICALS INC (AMLX) Latest news and press-releases to stay up to date.
Does AMYLYX PHARMACEUTICALS INC (AMLX) stock pay dividends?
AMLX does not pay a dividend.
When does AMYLYX PHARMACEUTICALS INC (AMLX) report earnings?
AMYLYX PHARMACEUTICALS INC (AMLX) will report earnings on 2025-05-07, before the market open.
What is the Price/Earnings (PE) ratio of AMYLYX PHARMACEUTICALS INC (AMLX)?
AMYLYX PHARMACEUTICALS INC (AMLX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.85).
What is the Short Interest ratio of AMYLYX PHARMACEUTICALS INC (AMLX) stock?
The outstanding short interest for AMYLYX PHARMACEUTICALS INC (AMLX) is 3.63% of its float. Check the ownership tab for more information on the AMLX short interest.
AMLX Technical Analysis
AMLX Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to AMLX. No worries on liquidiy or solvency for AMLX as it has an excellent financial health rating, but there are worries on the profitability.
AMLX Financial Highlights
Over the last trailing twelve months AMLX reported a non-GAAP Earnings per Share(EPS) of -1.85. The EPS decreased by -9150% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -103.49% | ||
| ROE | -132.24% | ||
| Debt/Equity | 0 |
AMLX Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 80% to AMLX. The Buy consensus is the average rating of analysts ratings from 12 analysts.
For the next year, analysts expect an EPS growth of -731.31% and a revenue growth -76.87% for AMLX